Literature DB >> 18268183

Gene-targeted therapies for the central nervous system.

Timothy M Miller1, Richard A Smith, Holly Kordasiewicz, Brian K Kaspar.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18268183     DOI： 10.1001/archneur.65.4.nnr70007

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  11 in total

1.  Antisense oligonucleotides and spinal muscular atrophy: skipping along.

Authors:  Arthur H M Burghes; Vicki L McGovern
Journal:  Genes Dev       Date:  2010-08-01       Impact factor: 11.361

2.  SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.

Authors:  Leah Winer; Dushyanth Srinivasan; Seung Chun; David Lacomis; Matthew Jaffa; Anne Fagan; David M Holtzman; Ed Wancewicz; C Frank Bennett; Robert Bowser; Merit Cudkowicz; Timothy M Miller
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

3.  An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.

Authors:  Timothy M Miller; Alan Pestronk; William David; Jeffrey Rothstein; Ericka Simpson; Stanley H Appel; Patricia L Andres; Katy Mahoney; Peggy Allred; Katie Alexander; Lyle W Ostrow; David Schoenfeld; Eric A Macklin; Daniel A Norris; Georgios Manousakis; Matthew Crisp; Richard Smith; C Frank Bennett; Kathie M Bishop; Merit E Cudkowicz
Journal:  Lancet Neurol       Date:  2013-03-29       Impact factor: 44.182

Review 4.  Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Authors:  Katharine A Nicholson; Merit E Cudkowicz; James D Berry
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

5.  New considerations in the design of clinical trials for amyotrophic lateral sclerosis.

Authors:  James D Berry; Merit E Cudkowicz
Journal:  Clin Investig (Lond)       Date:  2011-10

6.  Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease.

Authors:  Filip Simunovic; Ming Yi; Yulei Wang; Robert Stephens; Kai C Sonntag
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

Review 7.  Antisense oligonucleotides: treating neurodegeneration at the level of RNA.

Authors:  Sarah L DeVos; Timothy M Miller
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

8.  Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models.

Authors:  Alex McCampbell; Tracy Cole; Amy J Wegener; Giulio S Tomassy; Amy Setnicka; Brandon J Farley; Kathleen M Schoch; Mariah L Hoye; Mark Shabsovich; Linhong Sun; Yi Luo; Mingdi Zhang; Nicole Comfort; Bin Wang; Jessica Amacker; Sai Thankamony; David W Salzman; Merit Cudkowicz; Danielle L Graham; C Frank Bennett; Holly B Kordasiewicz; Eric E Swayze; Timothy M Miller
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

9.  Down-regulation of Toll-like receptor 4 gene expression by short interfering RNA attenuates bone cancer pain in a rat model.

Authors:  Liu Si Lan; Yang Jian Ping; Wang Li Na; Jiang Miao; Qiu Qiao Cheng; Ma Zhen Ni; Liu Lei; Li Cai Fang; Ren Chun Guang; Zhou Jin; Li Wei
Journal:  Mol Pain       Date:  2010-01-20       Impact factor: 3.395

10.  Direct intraventricular delivery of drugs to the rodent central nervous system.

Authors:  Sarah L DeVos; Timothy M Miller
Journal:  J Vis Exp       Date:  2013-05-12       Impact factor: 1.355
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.